• Merck's management commentary attributed third-quarter 2026 revenue growth of 5% to $18.1 billion to new products, oncology and animal health.
• Keytruda-family sales rose 6% excluding currency effects to $8.6 billion, driven by earlier-stage cancer uptake and metastatic demand.
• Non-GAAP operating expenses increased 12% to $7.4 billion, reflecting launch investments, pipeline spending and a licensing charge.
• Full-year revenue guidance narrowed to $66.8 billion–$67.3 billion; non-GAAP EPS guidance narrowed to $2.77–$2.82, with both midpoints raised.
• Favorable U.S. purchase timing boosted quarterly sales by approximately $550 million; Keytruda and Winrevair benefits are expected to reverse in the fourth quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.